Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain.
Fujita Y, Matsuoka H, Chiba Y, Tsurutani J, Yoshida T, Sakai K, Nakura M, Sakamoto R, Makimura C, Ohtake Y, Tanaka K, Hayashi H, Takahama T, Tanizaki J, Koyama A, Nishio K, Nakagawa K. Fujita Y, et al. Among authors: takahama t. Mol Clin Oncol. 2024 Nov 29;22(2):14. doi: 10.3892/mco.2024.2809. eCollection 2025 Feb. Mol Clin Oncol. 2024. PMID: 39720462 Free PMC article.
Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database.
Nakayama T, Takahama T, Chiba Y, Shiraishi N, Kawakami H, Yonesaka K, Nakagawa K, Hayashi H. Nakayama T, et al. Among authors: takahama t. J Immunother Cancer. 2024 Dec 18;12(12):e010130. doi: 10.1136/jitc-2024-010130. J Immunother Cancer. 2024. PMID: 39694703 Free PMC article.
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.
Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, Girard N, Patel VM, Takahama T, Owen SP, Reznick DM, Badin FB, Cicin I, Mekan S, Patel R, Zhang E, Karumanchi D, Garassino MC. Paz-Ares LG, et al. Among authors: takahama t. J Clin Oncol. 2024 Aug 20;42(24):2860-2872. doi: 10.1200/JCO.24.00733. Epub 2024 May 31. J Clin Oncol. 2024. PMID: 38843511 Free PMC article. Clinical Trial.
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, Goto M, Chiba Y, Tomida S, Ota T, Haratani K, Takahama T, Tanizaki J, Yoshida T, Iwasa T, Tanaka K, Takeda M, Hirano T, Yoshida H, Ozasa H, Sakamori Y, Sakai K, Higuchi K, Uga H, Suminaka C, Hirai T, Nishio K, Nakagawa K, Honjo T. Hayashi H, et al. Among authors: takahama t. J Clin Invest. 2024 Apr 1;134(7):e168318. doi: 10.1172/JCI168318. J Clin Invest. 2024. PMID: 38557498 Free PMC article.
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma.
Hazama D, Nakahama K, Kodama H, Miyazaki A, Azuma K, Kawashima Y, Sato Y, Ito K, Shiraishi Y, Miura K, Takahama T, Oizumi S, Namba Y, Ikeda S, Yoshioka H, Tsuya A, Yasuda Y, Negi Y, Hara A, Toda M, Tachihara M. Hazama D, et al. Among authors: takahama t. JTO Clin Res Rep. 2023 Nov 27;5(1):100613. doi: 10.1016/j.jtocrr.2023.100613. eCollection 2024 Jan. JTO Clin Res Rep. 2023. PMID: 38229769 Free PMC article.
138 results